Coagulation

Global Hemostasis/Coagulation Analyzers Market Size & Share, Application Analysis, Growth Trends, Key Players and Competitive Strategies - Forecast to 2026

Retrieved on: 
Tuesday, September 18, 2018
Anatomy, Coagulation system, Blood, Histology, Healing, Hematology, Hemostasis, Coagulation

The "Global Hemostasis/Coagulation Analyzers Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hemostasis/Coagulation Analyzers Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
  • Growing incidence of blood disorders is mainly attributed to the growth of hemostasis analyzers market.
  • The global hemostasis/coagulation analyzers market is segmented based on test types, product types, and end users.
  • Based on end users, the global hemostasis/coagulation analyzers market is studied for hospitals & clinics, diagnostic laboratories, and research institutions.

IDELVION® 3500 IU Vials Now Available to Provide Convenience to Patients

Retrieved on: 
Thursday, August 23, 2018
Blood, Coagulation system, Anatomy, Coagulation, Prothrombin complex concentrate, Factor IX, Haemophilia B, Bleeding, Coagulopathy, Haemophilia, CSL Behring, Factor VII

Hemophilia B is a congenital bleeding disorder characterized by deficient or defective factor IX; nearly all affected patients are male.

Key Points: 
  • Hemophilia B is a congenital bleeding disorder characterized by deficient or defective factor IX; nearly all affected patients are male.
  • According to the U.S. Centers for Disease Control and Prevention, the condition occurs in approximately one in 25,000 male births.
  • IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP), is used to control and prevent bleeding episodes in people with hemophilia B.
  • IDELVION might also increase the risk of abnormal blood clots in your body, especially if you have risk factors.

A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant

Retrieved on: 
Friday, June 22, 2018
CSL Behring, Behring, CSL Behring, Histology, Behring, Coagulation system, CSL Mobile, Coagulation, Blood plasma

In the news release, A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant, issued 22-Jun-2018 by CSL Behring over PR Newswire, we are advised by the company that the application deadline for the 2019 Prof. Heimburger Award cycle should read "November 15, 2018" rather than "October 14, 2018" as originally issued inadvertently.

Key Points: 
  • In the news release, A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant, issued 22-Jun-2018 by CSL Behring over PR Newswire, we are advised by the company that the application deadline for the 2019 Prof. Heimburger Award cycle should read "November 15, 2018" rather than "October 14, 2018" as originally issued inadvertently.
  • Their work may one day have a profound effect on the lives of people with coagulation disorders.
  • CSL Behring is a global biotherapeutics leader driven by its promise to save lives.
  • CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

ASH to Collaborate on Clinical Practice Guidelines on Diagnosis, Management of von Willebrand Disease

Retrieved on: 
Thursday, June 21, 2018
Anatomy, Blood, Coagulation system, Health, Histology, Autosomal dominant disorders, Von Willebrand disease, International Society on Thrombosis and Haemostasis, Von Willebrand factor, Medical guideline, Coagulation

This inherited condition results in the decreased production, absence, or abnormal function of the clotting protein von Willebrand factor.

Key Points: 
  • This inherited condition results in the decreased production, absence, or abnormal function of the clotting protein von Willebrand factor.
  • "These guidelines will provide clinicians and patients with clear recommendations for the timely diagnosis of VWD and appropriate management of symptoms.
  • ASH is pleased to collaborate with ISTH, NHF, and WFH to convene diverse expert panels and expand the reach of the guidelines across the globe."
  • This is the first time that ASH, ISTH, NHF, and WFH have collaborated on clinical practice guideline development and dissemination.

GLOBAL PLASMA FRACTIONATION MARKET 2018-2028

Retrieved on: 
Monday, June 11, 2018
Medicine, Clinical medicine, Anatomy, Blood, Medical signs, RTT, Immune system, Blood plasma fractionation, Coagulation, Globulin, Thrombocytopenic purpura, Hyperimmune globulin

NEW YORK, June 11, 2018 /PRNewswire/ -- Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia

Key Points: 
  • NEW YORK, June 11, 2018 /PRNewswire/ -- Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia
    In 2017, the global plasma fractionation market was valued at $24bn and is expected to grow at a CAGR of 9.0% in the first half of the forecast period.
  • In 2017, the immunoglobulins submarket held 44.0% of the global plasma fractionation market.
  • The 172-page report provides clear detailed insight into the global plasma fractionation market.
  • - This report also breaks down the revenue forecast for the global plasma fractionation market by type of product:

Groundbreaking POC hemostasis diagnostic to be presented at Major European Meetings

Retrieved on: 
Friday, May 25, 2018
Blood, Anatomy, Coagulation system, Hematology, Fibrinolytic system, Fibrinolysis, Blood tests, Thrombus, Coagulation, Hemostasis, Fibrin

On June 2nd, as part of the congress, Chief Scientific Officer Francesco Viola will be co-chairing the poster session entitled "Laboratory Coagulation Measurements".

Key Points: 
  • On June 2nd, as part of the congress, Chief Scientific Officer Francesco Viola will be co-chairing the poster session entitled "Laboratory Coagulation Measurements".
  • He will also be presenting a poster regarding a new cartridge in development for the Quantra Hemostasis Analyzer, which measures fibrinolysis in addition to clot stiffness and clot time parameters.
  • ESA Poster Details: A Novel Differential Assay to Quantify Fibrinolytic Function in Whole Blood with the Quantra Hemostasis Analyzer, June 2, 14:00-15:30; Poster e-Board 5.
  • The Quantra system is a rapid, easy-to-use diagnostic platform that utilizes consumable cartridges to run a panel of tests.

Hemostasis Reagents - In Vitro Diagnostics Market Analysis and Forecast Model

Retrieved on: 
Tuesday, May 22, 2018
Blood, Anatomy, Coagulation system, Coagulation, Hemostasis, Fibrin, Platelet, Thrombophilia, Coagulation testing

Hemostasis Reagents - In Vitro Diagnostics Market Analysis and Forecast Model is built to better visualize quantitative market trends of Hemostasis Reagents within the In Vitro Diagnostics market.

Key Points: 
  • Hemostasis Reagents - In Vitro Diagnostics Market Analysis and Forecast Model is built to better visualize quantitative market trends of Hemostasis Reagents within the In Vitro Diagnostics market.
  • Hemostasis Reagents Market is segmented into General Coagulation Tests, Coagulation Factors, Special Coagulation Tests, Platelet Factors, Fibrinolysis, Coagulation Inhibitors/Thrombophilia Markers and Other Hemostasis Reagents.
  • Each of the covered 39 country's market models are further segmented to provide granularity and pertinent data for respective market.
  • - Annualized total Hemostasis Reagents market revenue by segment and market outlooks from 2005-2024.

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

Retrieved on: 
Monday, May 21, 2018
Blood, Anatomy, Medicine, Transfusion medicine, Hematology, Coagulation system, Blood products, Platelet, Coagulation, Thrombocytopenia, Blood transfusion, Thrombus

This drug may decrease or eliminate the need for platelet transfusions, which are associated with risk of infection and other adverse reactions."

Key Points: 
  • This drug may decrease or eliminate the need for platelet transfusions, which are associated with risk of infection and other adverse reactions."
  • Platelets (thrombocytes) are colorless cells produced in the bone marrow that help form blood clots in the vascular system and prevent bleeding.
  • Thrombocytopenia is a condition in which there is a lower-than-normal number of circulating platelets in the blood.
  • People with chronic liver disease and people with certain blood clotting conditions may have an increased risk of developing blood clots when taking Doptelet.

Working to Improve Hemophilia A Testing: Precision BioLogic to present new data at WFH 2018 World Congress

Retrieved on: 
Friday, May 18, 2018
Coagulation system, Hemostasis, Coagulation, WFH, Medicine, Structure

HALIFAX, May 18, 2018 /PRNewswire/ -Precision BioLogic will present data at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland, May 20-24.

Key Points: 
  • HALIFAX, May 18, 2018 /PRNewswire/ -Precision BioLogic will present data at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland, May 20-24.
  • "Precision BioLogic has been developing, manufacturing and marketing hemostasis diagnostic products for more than 25 years," says Paul Empey, President & CEO of Precision BioLogic.
  • Precision BioLogic plans to commercialize the kit and will seek clearance from regulatory authorities around the globe beginning in late 2018.
  • Unfortunately, up to 30% of people with hemophilia A develop inhibitors, an immune response to treatment with clotting factor concentrates.

Global Point-of-Care Coagulation Testing Market 2018-2022: Key Vendors are Abbott, Danaher, F. Hoffmann-La Roche, Medtronic, Siemens & Sysmex

Retrieved on: 
Friday, May 11, 2018
Blood tests, Market research, Blood, Coagulation, Coagulation system, Market analysis, Structure

The "Global Point-of-Care Coagulation Testing Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Point-of-Care Coagulation Testing Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • The global point-of-care coagulation testing market to grow at a CAGR of 6.11% during the period 2018-2022.
  • Global Point-of-Care Coagulation Testing Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts.
  • The growing focus on the development of personalized medicines is identified as one of the key trends that will gain traction in the point-of-care coagulation testing market.